NewAmsterdam Pharma files sale notice for 443,707 shares

NewAmsterdam Pharma submitted a Form 144 notice reporting the proposed sale of 443,707 ordinary shares by option exercise on 03/02/2026 for cash on Nasdaq.

Rhea-AI Filing Summary

NewAmsterdam Pharma submitted a Form 144 notice reporting the proposed sale of 443,707 ordinary shares by option exercise on 03/02/2026 for cash on Nasdaq. The filing also lists recent sales by Michael Davidson totaling 318,145 shares across 01/07/2026–02/26/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does NAMS Form 144 report?

It reports a proposed sale of 443,707 ordinary shares. The notice states the shares are to be sold via option exercise for cash on 03/02/2026 on Nasdaq and includes recent disposals by Michael Davidson.

Who is the seller named in the NAMS Form 144 filing?

Michael Davidson is the named individual associated with recent sales. The filing lists multiple sales by him totaling 11852, 64708, 58253, and 183332 shares on specific dates in January–February 2026.

How many shares were sold by Michael Davidson in the past three months?

He sold a combined 318,145 shares in the past three months. The filing lists sales of 11,852; 64,708; 58,253; and 183,332 shares on 01/07/2026, 02/24/2026, 02/25/2026, and 02/26/2026, respectively.

When is the 443,707-share sale scheduled to occur?

The proposed sale is dated 03/02/2026. The filing indicates the shares are linked to an option exercise and the sale method is listed as cash on Nasdaq on that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:10 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001573785
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NewAmsterdam Pharma Company N.V.
SEC File Number	001-41562
Address of Issuer	Gooimeer 2-35 DC Naarden NETHERLANDS 1411
Phone	31-0-35-206-2971
Name of Person for Whose Account the Securities are To Be Sold	Michael H. Davidson
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	J.P. Morgan Securities LLC 270 Park Avenue - 10th Floor New York NY 10017	443707	15733850.22	114975422	03/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	03/02/2026	Option Exercise	Issuer			443707	03/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael Davidson Care of NewAmsterdam Pharma Company N.V. Gooimeer 2-35 DC Naarden P7 1411	Ordinary Shares	01/07/2026	11852	410888.61
Michael Davidson Care of NewAmsterdam Pharma Company N.V. Gooimeer 2-35 DC Naarden P7 1411	Ordinary Shares	02/24/2026	64708	2338922.43
Michael Davidson Care of NewAmsterdam Pharma Company N.V. Gooimeer 2-35 DC Naarden P7 1411	Ordinary Shares	02/25/2026	58253	2056319.25
Michael Davidson Care of NewAmsterdam Pharma Company N.V. Gooimeer 2-35 DC Naarden P7 1411	Ordinary Shares	02/26/2026	183332	6255159.51

144: Remarks and Signature

Remarks
Date of Notice	03/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Michael H. Davidson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)